NanoString Technologies - Prosigna Breast Cancer Prognostic Gene Signature Assay
Manufactured by NanoString Technologies
The only PAM50-based breast cancer genomic signature
The Prosigna Breast Cancer Prognostic Gene Signature Assay is a qualitative in vitro diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score to assess a patient’s risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative
(Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin-embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma.
(Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin-embedded (FFPE) breast tumor tissue previously diagnosed as invasive breast carcinoma.
Active Questions & AnswersAsk a Question
There are no current Discussions
DNA Sequencing Reagents Service ProvidersView All (3)
Documents & ManualsView All Documents
Features of Prosigna Breast Cancer Prognostic Gene Signature Assay
- The only PAM50-based breast cancer genomic signature * The only genomic breast cancer assay that can be run in your pathology lab * The only test that is FDA 510(k) cleared for FFPE tissue
General Specifications
There are no General Specifications available.